FEASIBILITY STUDY OF AMORPHOUS SILICON FAÇADES IN ANDALUSIA
Reduction in HVAC energy demands
Internal Rate of Return
The installation of a double skin on the façade of this building belonging to the multi-national pharmaceutical company Pfizer creates a spectacular pixelated mosaic of glass of different shades and sizes especially created for this project.
The façade features an active surface area of 550 m2 of amorphous silicon glass modules with a semi-transparency degree of 20% (L vision).
This project has an installed power capacity of 19.3 kWp, generating 32,000 kWh of energy per year and preventing the consumption of 19 barrels of oil yearly.
This building, envisaged as an area for research into the genetic basis of diseases, employs this photovoltaic double skin for the production of a large amount of the energy it consumes, specifically 1,814 lights in the building itself.
Furthermore, the double skin thermally and acoustically insulates the building, providing significant savings in heating and air handling systems.
- Total area -1.062 M2
- Electricity generated per year - 31.837 kWh
- Total light points operating 4 hours a day - 1.814 lighting points
- Avoided CO2 emissions per year - 21.330CO2
- Barrels of oil saved per year -19 barrels
"Our aim is to continue with our commitment to energetic efficiency and the use of renewable energy, provided that it is profitable and that it makes sense”.